De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Austar Lifesciences Balans Gezondheid
Financiële gezondheid criteriumcontroles 3/6
Austar Lifesciences heeft een totaal eigen vermogen van CN¥780.6M en een totale schuld van CN¥386.3M, wat de schuld-eigenvermogensverhouding op 49.5% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥2.1B en CN¥1.4B.
Belangrijke informatie
49.5%
Verhouding schuld/eigen vermogen
CN¥386.27m
Schuld
| Rente dekkingsratio | n/a |
| Contant | CN¥139.98m |
| Aandelen | CN¥780.63m |
| Totaal verplichtingen | CN¥1.36b |
| Totaal activa | CN¥2.14b |
Recente financiële gezondheidsupdates
Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?
Mar 28
We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt
Sep 28Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden
Mar 31Is Austar Lifesciences (HKG:6118) A Risky Investment?
Apr 06Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet
Oct 24Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly
Mar 31Recent updates
Investors Aren't Buying Austar Lifesciences Limited's (HKG:6118) Revenues
Aug 28We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package
May 24Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive
Apr 18Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?
Mar 28Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump
Feb 12Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues
Dec 22We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt
Sep 28Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden
Mar 31Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Sep 19Is Austar Lifesciences (HKG:6118) A Risky Investment?
Apr 06Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet
Oct 24With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting
Sep 27If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late
May 31Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly
Mar 31Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?
Mar 01Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Feb 01
Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?
Jan 11Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly
Dec 21Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?
Dec 07Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like
Nov 23Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( CN¥1.6B ) 6118 } overtreffen de korte termijn passiva ( CN¥1.2B ).
Langlopende schulden: De kortetermijnactiva 6118 ( CN¥1.6B ) overtreffen de langetermijnschulden ( CN¥168.6M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 31.5% ) 6118 wordt als voldoende beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van 6118 is de afgelopen 5 jaar gestegen van 4.1% naar 49.5%.
Schuldendekking: De schuld van 6118 wordt niet goed gedekt door de operationele kasstroom ( 5.6% ).
Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van 6118 op haar schulden goed worden gedekt door EBIT.